NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
Publication
, Journal Article
Flaig, TW; Spiess, PE; Abern, M; Agarwal, N; Bangs, R; Boorjian, SA; Buyyounouski, MK; Chan, K; Chang, S; Friedlander, T; Greenberg, RE ...
Published in: J Natl Compr Canc Netw
August 2022
The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non-muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non-muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody-drug conjugates for metastatic bladder cancer.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
August 2022
Volume
20
Issue
8
Start / End Page
866 / 878
Location
United States
Related Subject Headings
- Urinary Bladder Neoplasms
- Oncology & Carcinogenesis
- Neoplasm Staging
- Neoplasm Recurrence, Local
- Neoplasm Invasiveness
- Male
- Humans
- Carcinoma, Transitional Cell
- Administration, Intravesical
Citation
APA
Chicago
ICMJE
MLA
NLM
Flaig, T. W., Spiess, P. E., Abern, M., Agarwal, N., Bangs, R., Boorjian, S. A., … Gurski, L. A. (2022). NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw, 20(8), 866–878. https://doi.org/10.6004/jnccn.2022.0041
Flaig, Thomas W., Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, et al. “NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.” J Natl Compr Canc Netw 20, no. 8 (August 2022): 866–78. https://doi.org/10.6004/jnccn.2022.0041.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, et al. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 Aug;20(8):866–78.
Flaig, Thomas W., et al. “NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.” J Natl Compr Canc Netw, vol. 20, no. 8, Aug. 2022, pp. 866–78. Pubmed, doi:10.6004/jnccn.2022.0041.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 Aug;20(8):866–878.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
August 2022
Volume
20
Issue
8
Start / End Page
866 / 878
Location
United States
Related Subject Headings
- Urinary Bladder Neoplasms
- Oncology & Carcinogenesis
- Neoplasm Staging
- Neoplasm Recurrence, Local
- Neoplasm Invasiveness
- Male
- Humans
- Carcinoma, Transitional Cell
- Administration, Intravesical